Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | GAA | P10253 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10662571 | 0.78 | KDM4E (0.67) | KDM4EALDH1A1GAARAB9AHPGD | |
| SCHEMBL6296160 | 0.76 | KDM4E (0.69) | KDM4EALDH1A1GAARAB9AHPGD | |
| SCHEMBL14031287 | 0.71 | KDM4E (0.57) | KDM4EALDH1A1GAARAB9AHPGD | |
| SCHEMBL2575457 | 0.71 | BCHE (0.46) | ALDH1A1GAAHPGDSMN1; SMN2LMNA | |
| SCHEMBL6817059 | 0.70 | MAPT (0.62) | KDM4EALDH1A1GAARAB9AHPGD | |
| SCHEMBL457214 | 0.70 | KDM4E (0.56) | KDM4EALDH1A1GAARAB9AHPGD | |
| SCHEMBL4346250 | 0.69 | MEN1 (0.59) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4347342 | 0.69 | MEN1 (0.59) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL2764566 | 0.69 | ATM (0.61) | KDM4EALDH1A1GAARAB9AHPGD | |
| SCHEMBL4357296 | 0.68 | POLB (0.56) | ALDH1A1HPGDSMN1; SMN2KMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | disclosed |
| CN-101516860-B | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG | 2012-06-27 | — | — | CN | disclosed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | NOVARTIS AG | 2010-01-14 | — | — | US | disclosed |
| CN-101516860-A | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2066647-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008031594-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| EP-1900729-A1 | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors | Novartis AG (CH) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | JAK2, JAK3, JAK1 | KDM4E 715/4885ALDH1A1 1245/4885GAA 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.